ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO713

Assessing Bleeding Risk in CKD Using Global Coagulation Assays

Session Information

Category: Pathology and Lab Medicine

  • 1602 Pathology and Lab Medicine: Clinical

Authors

  • Langsford, David, Northern Health, Melbourne, Victoria, Australia
  • Lui, Brandon, University of Melbourne, Melbourne, Victoria, Australia
  • Pianta, Timothy J., Northern Health, Melbourne, Victoria, Australia
  • Barit, David, Northern Health, Melbourne, Victoria, Australia
  • Nandurkar, Harshal, Northern Health, Melbourne, Victoria, Australia
  • Ho, Prahlad W., Northern Health, Melbourne, Victoria, Australia
  • Lim, Yin H., Northern Health, Melbourne, Victoria, Australia
Background

Later stage CKD patients are often clinically hypocoaguable. Current coagulation studies do not sufficiently assess this risk. Global coagulation studies (GCA) are functional studies that can better describe bleeding and thrombosis risk. GCA includes whole blood thromboelastography (TEG), platelet-poor calibrated automated thrombogram (CAT), overall haemostatic potential (OHP). TEG is well established in the management of major haemorrhage and massive transfusion. We aim to evaluate using GCA in CKD patients to help define bleeding or thrombosis risks.

Methods

We prospectively recruited 2 groups of stable CKD patients. Pre-dialysis with eGFR<30 ml/min/1.73m2 (n=24) and dialysis patients (n=46 haemodialysis, n=10 peritoneal dialysis) were compared to healthy controls (n=138). Baseline renal, hematological investigations and GCA were compared using t-test and chi-square statistics.

Results

Compared to controls (67% female, mean age 42, creatinine 70umol/L) predialysis CKD (46% female, mean age 70, creatinine 237umol/L, urea 18.6mmol/L, eGFR 22 ml/min/1.7m2) had increased von Willebrand factor (VWF) antigen (223 vs 102%, p<0.001), factor VIII (208 vs 108%, p<0.001) and D-dimer (1188 vs 430, p<0.001). Pre-dialysis CKD were prothrombotic with increased maximum amplitude (MA, a measure of clot strength) of 68 vs 60mm (p<0.01) compared to controls. In predialysis CKD, there was no association between urea or eGFR and MA. Thrombin generation (peak thrombin 269 vs 219nM, p<0.01) and fibrin generation (OHP 41 vs 29, p<0.01) were increased with impaired fibrinolysis (OFP 42 vs 50%, p<0.01) compared with controls. Dialysis patients (38% female, mean age 66) also had increased clot strength (MA 70mm, p<0.01) and reduced fibrinolysis (OHP 41 U, OFP 40%, p<0.01) compared to controls. Measures of clot strength and overall fibrinolysis were not significantly different between pre-dialysis and dialysis patients.

Conclusion

Contrary to expectation, pre-dialysis CKD and dialysis patients were not found to be hypocoaguable using functional coagulation tests. Both groups were found to have markers conferring increased prothrombotic risk: elevated vWF, increased TEG measures and impaired fibrinolysis. The clinical significance of these results and the use of GCA to stratify both thrombotic and bleeding risk warrants further investigation.